Article
Integration of genetic, clinical, and INR data to refine warfarin dosing.
Clinical pharmacology and therapeutics - 1 May 2010
Lenzini P, Wadelius M, Kimmel S, Anderson J L, Jorgensen A L, Pirmohamed M, Caldwell M D, Limdi N, Burmester J K, Dowd M B, Angchaisuksiri P, Bass A R, Chen J, Eriksson N, Rane A, Lindh J D, Carlquist J F, Horne B D, Grice G, Milligan P E, Eby C, Shin J, Kim H, Kurnik D, Stein C M, McMillin G, Pendleton R C, Berg R L, Deloukas P, Gage B F
Abstract excerpt
Well-characterized genes that affect warfarin metabolism (cytochrome P450 (CYP) 2C9) and sensitivity (vitamin K epoxide reductase complex 1 (VKORC1)) explain one-third of the variability in therapeutic dose before the international normalized ratio (INR) is measured. To determine genotypic relevance after INR becomes available, we derived clinical and pharmacogenetic refinement algorithms on the basis of INR...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.